Blackrock Neurotech, a brain-computer-interface (BCI) technology company, secures $200million in funding. The firm plans to further increase its R&D activities in addition to using the cash for the commercialization and roll-out of its medical solutions, which have already been used by over forty people.
Blackrock Neurotech is a human BCI company that was founded in 2008 by Dr. Florian Solzbacher and Marcus Gerhardt. Its goal is to assist the millions of people worldwide who suffer from neurological disorders, paralysis, lost function, and other conditions that prevent them from walking, seeing, hearing, feeling, or speaking.
Read also – TX-based Backflip Secures $15Million in Series A Round Funding – FUNDING NEWS
Early users were able to see, hear, feel, and move again because to its precise electrode technology, which is at the heart of many global advancements in BCI. Furthermore, Blackrock creates cutting-edge platform tools for neuroprosthetics, neural engineering, and neuroscience, supporting innovative research at more than 500 top universities throughout the globe.
Florian Solzbacher said: “My life’s dream has been to help and restore function in people who lost it and to advance technologies that revolutionize healthcare and the world around us. This ambitious, long-term endeavor requires dedicated and visionary partners. With its commitment to seeking out and nurturing technology that will help many people and push mankind forward, we couldn’t dream of a better partner than Tether to bring our shared vision to life.”
About Blackrock Neurotech
A group of the top engineers, neuroscientists, and visionaries in the world work together at Blackrock Neurotech. Their goal is to restore the ability to walk, speak, see, hear, and feel for those who suffer from neurological illnesses. They are developing the next wave of neural implants, such as implanted brain-computer interfaces that help people with neurological conditions regain their freedom and function.
